Pain

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Retrieved on: 
Wednesday, April 10, 2024
Annual, Annual report, Tax, BioNTech, Coronavirus, Inflammation, Acquisition, Management, Dermatology, Depreciation, Pain, Growth, Parallel, Pharmaceutical industry

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Key Points: 
  • Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
    The issuer is solely responsible for the content of this announcement.
  • » Adjusted consolidated EBITDA margin: 27.3%
    Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023.
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) declined by 13.8% to EUR 310.2 million (prior-year period: EUR 359.8 million).
  • We exceeded our guidance for consolidated revenue and reached the upper end of the forecast range for adjusted EBITDA.

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Retrieved on: 
Tuesday, April 9, 2024
Blood pressure, Ethanol, Collateral damage, Disease, Nervous system, Patient, Renal artery, Pain, AMIX, Hypertension, Pharmaceutical industry

THE WOODLANDS, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Key Points: 
  • The preclinical porcine model study was designed to assess the ability of the Company’s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery.
  • These results strongly demonstrate the potential of Autonomix’s sensing technology to successfully locate nerves around the renal artery.
  • These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension.
  • The successful completion of this preclinical study provides us with confidence in the potential of our sensing technology to ultimately make renal denervation safer, faster, and more effective.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Retrieved on: 
Tuesday, April 9, 2024
Research, NCP, KOL, ARVO, DED, Pain, FDA

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Key Points: 
  • LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.
  • The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
  • OKYO is planning to make a presentation at “Dry Horizons Symposium Navigating the Future of Dry Eye Research”, an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
Monday, April 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

Introducing Protomentum – The Ideal Accelerated Product Development Partner

Retrieved on: 
Monday, April 8, 2024
Online, NOVA, HR, ASAP, Documentation, Headache, CNC, Electronics, FedEx, System, Pain, Risk management

SYDNEY, NOVA SCOTIA, April 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Protocase, the leader in B2B custom electronic enclosures and precision sheet metal fabrication for a wide range of industries including aerospace via its ProtoSpace division, is thrilled to announce the launch of its new division: Protomentum. This innovative venture is poised to revolutionize product development by providing an all-encompassing solution for founders, venture capitalists, innovators and established companies seeking rapid time-to-market via a single best-in-class partner with decades of proven processes and experience. Great products only happen after multiple iterations, and our ultra-fast manufacturing lets you iterate and refine quickly, achieving a much higher standard than possible with fewer, slower development cycles. Additionally, Protomentum's flexible manufacturing enables you to make multiple versions for market quickly for high-value, low-volume products.

Key Points: 
  • In today’s fast-paced business landscape where efficiency is do or die, time is of the essence, especially for early-stage companies and first-time product runs.
  • However, the traditional product development process often hinders progress due to fragmented workflows.
  • Current standalone options for product design are not ideal; the choice is either hiring an external design agency, or having mechanical designers/engineers on staff, both of which are cost prohibitive.
  • That’s why we created Protomentum, the one-stop solution for rapid product development and a true game changer in manufacturing solutions.

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Retrieved on: 
Monday, April 8, 2024
Organization, Clobetasol, Disease, Inflammation, Near-sightedness, Sale, NDA, Mydriasis, Pain, FDA, Pharmaceutical industry

In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.

Key Points: 
  • In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.
  • “The pediatric progressive myopia market represents a significant opportunity for Eyenovia both in the United States and China.
  • This disease, for which there are no FDA-approved pharmaceutical treatments, has been called an epidemic by several medical and optometric organizations.
  • Eyenovia does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved.

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

Retrieved on: 
Monday, April 8, 2024
Venus, Magnetic field, Communication, System, Spasm, Abdomen, History, Research, Human, Ministry of Health, Cellulite, Lipolysis, Annual report, Pain, Ministry, FDA

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.

Key Points: 
  • TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
  • The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
  • The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators.
  • “The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept.

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Inflammation, Pain, Patient, OCS

Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.

Key Points: 
  • Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.
  • The results showed that 57.2% of patients treated with OCS-01 were inflammation free (i.e.
  • absence of anterior chamber cells) at Day 15 (vs. 24.0% with vehicle, p
  • The two Phase 3 OPTIMIZE trials are expected to support an NDA submission.